Tenax Therapeutics enrolls first patient in Phase 3 LEVEL study for TNX-103 in PH-HFpEF; topline data expected H2 2025

TENAX THERAPEUTICS, INC.

First patient enrolled in Phase 3 LEVEL study of oral TNX-103 (levosimendan) for PH-HFpEF; 152-patient trial.
Over 40 U.S. and Canadian sites agreed to participate, including Mayo, Harvard, Northwestern.
Topline data forecast for second half of 2025.
FDA does not require long-term CV outcomes trial, reducing cost and time to registration.
Patent estate protects TNX-103 through at least 2040.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.